Inactive Instrument

Share ownership Phytopharm plc London S.E.

GB0006869720

Biotechnology & Medical Research

End-of-day quote London S.E.
- ^GBX	-

07-13	Oil rises as Iran escalation keeps FTSE subdued	AN
07-13	Ixico notes ending of Huntington's disease programmes	AN

Share class: Phytopharm plc

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	218,974,282	195,378,829 ( 89.22 %)	0	89.22 %

Major shareholders: Phytopharm plc

Name	Stocks	%	Valuation
Octopus Investments Ltd. 11.82 %	25,878,817	11.82 %	3 M p
Unicorn Asset Management Ltd. 9.927 %	21,737,555	9.927 %	2 M p
Gresham House Asset Management Ltd. 7.382 %	16,164,709	7.382 %	2 M p
BGF Investment Management Ltd. 5.885 %	12,887,000	5.885 %	1 M p
Rathbones Investment Management Ltd. 4.128 %	9,040,000	4.128 %	951 008 p
Maven Capital Partners UK LLP 3.691 %	8,081,651	3.691 %	850 190 p
Canaccord Genuity Wealth Ltd. 3.347 %	7,328,224	3.347 %	770 929 p
Riverrock Capital Ltd. (United Kingdom) 1.762 %	3,857,566	1.762 %	405 816 p
Hargreaves Lansdown Asset Management Ltd. 1.367 %	2,994,000	1.367 %	314 969 p
Bram Goorden 1.092 %	2,390,501	1.092 %	251 481 p
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	50.75%
Individuals	1.31%
Others	0.08%
Unknown	47.86%

Based on 1000 largest holdings

Geographical origin of shareholders

United Kingdom	50.67%
Individuals	1.31%
Luxembourg	0.08%
United States	0.07%
Switzerland	0.01%

Based on 1000 largest holdings

IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.

Employees

Sector

Biotechnology & Medical Research

More about the company